Opus Genetics insider plans Rule 144 stock sale

George Magrath filed a notice to sell restricted securities of Opus Genetics, Inc. under SEC Rule 144.

Rhea-AI Filing Summary

George Magrath filed a notice to sell restricted securities of Opus Genetics, Inc. under SEC Rule 144. The planned sale covers 9,475 shares of common stock through Jefferies LLC, with an aggregate market value of $28,898.75 and approximately 83,000,000 shares of the same class outstanding. The shares derive from vested restricted stock units that vested on January 22, 2026, and the proposed sale date is July 23, 2026. In the prior three months, 9,511 shares of Opus Genetics common stock were sold for $49,647.42.

Key Figures

Shares to be sold: 9,475 shares Aggregate market value of planned sale: $28,898.75 Shares outstanding: 83,000,000 shares +5 more

8 metrics

Shares to be sold 9,475 shares Planned Rule 144 sale of Opus Genetics common stock through Jefferies LLC

Aggregate market value of planned sale $28,898.75 Value of 9,475 Opus Genetics shares to be sold under Rule 144

Shares outstanding 83,000,000 shares Approximate Opus Genetics common shares of the class outstanding

Vested RSU shares 9,475 shares Common shares from vested restricted stock units vested on January 22, 2026

Prior 3-month sales volume 9,511 shares Opus Genetics shares sold during the past three months

Prior 3-month sales value $49,647.42 Total consideration for 9,511 shares sold in the past three months

Proposed sale date 07/23/2026 Proposed date for the Rule 144 sale on Nasdaq

RSU vesting date 01/22/2026 Date the restricted stock units vested into common shares

Key Terms

Form 144, Rule 144, Vested Restricted Stock Units, aggregate market value, +1 more

5 terms

Form 144 regulatory

"filed a notice to sell restricted securities of Opus Genetics, Inc. under Form 144"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 regulatory

"plans to sell 9,475 shares of Opus Genetics common stock under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Vested Restricted Stock Units financial

"originates from Vested Restricted Stock Units in Opus Genetics, Inc."

aggregate market value financial

"planned sale has an aggregate market value of $28,898.75"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

common stock financial

"9,475 shares of Opus Genetics common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing related to IRD and Opus Genetics disclose?

The filing discloses that George Magrath plans to sell 9,475 shares of Opus Genetics common stock under Rule 144, with an aggregate market value of $28,898.75 and a proposed sale date of July 23, 2026.

How many Opus Genetics shares is George Magrath planning to sell in this Form 144?

George Magrath plans to sell 9,475 shares of Opus Genetics common stock. These shares come from vested restricted stock units that vested on January 22, 2026, and are to be sold through Jefferies LLC on or after July 23, 2026.

What is the market value and outstanding share count noted in the IRD-related Form 144?

The planned sale has an aggregate market value of $28,898.75, and the filing notes approximately 83,000,000 shares of Opus Genetics common stock outstanding, providing context for the relative size of the proposed disposition.

What is the origin and vesting date of the Opus Genetics shares in this Form 144?

The 9,475 shares to be sold originate from vested restricted stock units in Opus Genetics, Inc. These RSUs vested on January 22, 2026, and the resulting common shares are now eligible for resale under Rule 144.

Were any Opus Genetics shares sold in the three months prior to this Form 144 filing?

Yes. In the preceding three months, 9,511 shares of Opus Genetics common stock were sold for a total of $49,647.42. This prior activity is disclosed as part of the Rule 144 reporting requirements for recent sales.

Which broker is handling the planned Rule 144 sale for the Opus Genetics shares?

The planned Rule 144 sale of 9,475 Opus Genetics shares will be handled by Jefferies LLC, located at 520 Madison Ave, New York, NY 10022, with the shares listed for trading on the Nasdaq market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 05:18 PM Accepted by SEC EDGAR 07/23/2026 - 05:17 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001999390
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Opus Genetics, Inc.
SEC File Number	001-34079
Address of Issuer	8 DAVIS DRIVE SUITE 220 DURHAM NORTH CAROLINA 27713
Phone	(984) 884-6030
Name of Person for Whose Account the Securities are To Be Sold	Magrath George
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave New York NY 10022	9475	28898.75	83000000	07/23/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/22/2026	Vested Restricted Stock Units	Opus Genetics, Inc.			9475	01/22/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
George Magrath 8 Davis Drive Ste.220 Durham NC 27709	Opus Genetics, Inc.	04/23/2026	9511	49647.42

144: Remarks and Signature

Remarks	Shares to be sold automatically on behalf of the reporting person, as required by the Company to satisfy tax withholding that arose in connection with a vesting and settlement event from a RSU award. This transaction will not represent a discretionary trade by the reporting person.
Date of Notice	07/23/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	George Magrath
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)